From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

Ettore D’Argento, Sabrina Rossi, Giovanni Schinzari, Antonia Strippoli, Michele Basso, Alessandra Cassano, Carlo Barone

Research output: Contribution to journalReview article

Abstract

New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.

Original languageEnglish
Article number59
JournalCurrent Treatment Options in Oncology
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Platinum
Immunotherapy
Patient Selection
Habits
Comorbidity
Smoking
Neoplasms

Keywords

  • Antiangiogenic agents
  • Immunotherapy
  • Non-small-cell lung cancer
  • Second line

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

D’Argento, E., Rossi, S., Schinzari, G., Strippoli, A., Basso, M., Cassano, A., & Barone, C. (2016). From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? Current Treatment Options in Oncology, 17(12), [59]. https://doi.org/10.1007/s11864-016-0437-x

From 2000 to 2016 : Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? / D’Argento, Ettore; Rossi, Sabrina; Schinzari, Giovanni; Strippoli, Antonia; Basso, Michele; Cassano, Alessandra; Barone, Carlo.

In: Current Treatment Options in Oncology, Vol. 17, No. 12, 59, 01.12.2016.

Research output: Contribution to journalReview article

D’Argento, E, Rossi, S, Schinzari, G, Strippoli, A, Basso, M, Cassano, A & Barone, C 2016, 'From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?', Current Treatment Options in Oncology, vol. 17, no. 12, 59. https://doi.org/10.1007/s11864-016-0437-x
D’Argento, Ettore ; Rossi, Sabrina ; Schinzari, Giovanni ; Strippoli, Antonia ; Basso, Michele ; Cassano, Alessandra ; Barone, Carlo. / From 2000 to 2016 : Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. In: Current Treatment Options in Oncology. 2016 ; Vol. 17, No. 12.
@article{4233f38d51534a66bc4ac580b8b90549,
title = "From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?",
abstract = "New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 {\%}. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.",
keywords = "Antiangiogenic agents, Immunotherapy, Non-small-cell lung cancer, Second line",
author = "Ettore D’Argento and Sabrina Rossi and Giovanni Schinzari and Antonia Strippoli and Michele Basso and Alessandra Cassano and Carlo Barone",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s11864-016-0437-x",
language = "English",
volume = "17",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - From 2000 to 2016

T2 - Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

AU - D’Argento, Ettore

AU - Rossi, Sabrina

AU - Schinzari, Giovanni

AU - Strippoli, Antonia

AU - Basso, Michele

AU - Cassano, Alessandra

AU - Barone, Carlo

PY - 2016/12/1

Y1 - 2016/12/1

N2 - New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.

AB - New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.

KW - Antiangiogenic agents

KW - Immunotherapy

KW - Non-small-cell lung cancer

KW - Second line

UR - http://www.scopus.com/inward/record.url?scp=84992147341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992147341&partnerID=8YFLogxK

U2 - 10.1007/s11864-016-0437-x

DO - 10.1007/s11864-016-0437-x

M3 - Review article

AN - SCOPUS:84992147341

VL - 17

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 12

M1 - 59

ER -